Dr. Rosalyn Juergens, McMaster University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.

[powerpress]

For our upcoming lung cancer tweetchat (hashtag #lcsm) on Thursday, August 22nd at 8 PM Eastern, 5 PM Pacific, we're going to be covering the important topic of costs of cancer drugs and procedures, how that's affecting patient care, whether pricing is fair, and whether there is a sense of value in the drugs and treatments being offered.

Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

[powerpress]

Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

[powerpress]

Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.

[powerpress]

Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).

[powerpress]

A couple of weeks ago, I described the new concept of a "tweetchat" about lung cancer, and we're about to have our second of these tomorrow: Thursday, August 8th, at 8 PM Eastern, 5 PM Pacific time.

Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.

[powerpress]